Get the Stockscreener App
1.81
4.23%
-0.08
After Hours:
1.82
0.01
+0.55%
Tenax Therapeutics Inc stock is traded at $1.81, with a volume of 1.99M.
It is down -4.23% in the last 24 hours and down -21.98% over the past month.
Tenax Therapeutics Inc is a phase three, development-stage pharmaceutical company focused on identifying and developing therapeutics that address cardiovascular and pulmonary diseases with high unmet medical need, with an initial therapeutic focus on pulmonary hypertension. Its drug development pipeline comprises: Levosimendan, a novel, first-in-class K-ATP activator and calcium sensitizer developed for intravenous use in hospitalized patients with acutely decompensated heart failure; and Imatinib, as a potential therapy for pulmonary arterial hypertension. The company is currently conducting clinical trials only for levosimendan as its prioritized product candidate to evaluate its potential to help patients with pulmonary hypertension.
See More
Previous Close:
$1.89
Open:
$1.88
24h Volume:
1.99M
Relative Volume:
0.38
Market Cap:
$67.74M
Revenue:
-
Net Income/Loss:
$-57.91M
P/E Ratio:
-1.2937
EPS:
-1.3991
Net Cash Flow:
$-38.14M
1W Performance:
-4.74%
1M Performance:
-21.98%
6M Performance:
-87.07%
1Y Performance:
-73.42%
1-Day Range:
$1.81
$1.93
1-Week Range:
$1.80
$1.95
52-Week Range:
$1.31
$19.40
Tenax Therapeutics Inc Stock (TENX) Company Profile
Name
Tenax Therapeutics Inc
Sector
Industry
Phone
919-855-2100
Address
101 GLEN LENNOX DRIVE, CHAPEL HILL, NC
Compare TENX vs VRTX, REGN, MRNA, ARGX, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
TENX
Tenax Therapeutics Inc
|
1.81 | 67.74M | 0 | -57.91M | -38.14M | -1.3991 |
VRTX
Vertex Pharmaceuticals Inc
|
526.19 | 133.37B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
788.04 | 81.13B | 14.92B | 4.42B | 3.79B | 41.04 |
MRNA
Moderna Inc
|
198.88 | 79.40B | 2.23B | -3.19B | -1.60B | -8.1462 |
ARGX
Argen X Se Adr
|
959.49 | 60.03B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
204.97 | 43.93B | 742.00K | -1.37B | -1.07B | -7.0731 |
Tenax Therapeutics Inc Stock (TENX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-17-26 | Initiated | Cantor Fitzgerald | Overweight |
| Sep-08-25 | Initiated | Piper Sandler | Overweight |
| Oct-24-24 | Initiated | Leerink Partners | Outperform |
| Oct-14-24 | Initiated | Guggenheim | Buy |
| Sep-30-24 | Initiated | William Blair | Outperform |
| May-18-17 | Upgrade | Ladenburg Thalmann | Neutral → Buy |
| Dec-16-14 | Initiated | MLV & Co | Buy |
| Nov-18-14 | Initiated | WallachBeth | Buy |
View All
Tenax Therapeutics Inc Stock (TENX) Latest News
Wall Street Analysts Predict a 121.36% Upside in Tenax Therapeutics (TENX): Here's What You Should Know - Eastern Progress
Independent Director of Tenax Therapeutics Declan Doogan Buys 2,331% More Shares - webull.com
Tenax Therapeutics, Inc.(NasdaqCM: TENX) added to S&P Global BMI Index - marketscreener.com
Tenax Therapeutics Inc (NASDAQ: TENX) Share Price, TENX Stock News, TENX Share Price & Updates - kalkine.com.au
Tenax Therapeutics director Declan Doogan buys $101,760 in shares - Investing.com India
Director Declan Doogan Buys 53,000 Shares of Tenax Therapeutics Inc (TENX) - GuruFocus
Tenax Therapeutics director Declan Doogan buys $101,760 in shares By Investing.com - Investing.com Canada
ING Groep NV Exits Tenax Therapeutics Inc (TENX) Position in Ful - GuruFocus
Piper Sandler Remains a Buy on Tenax Therapeutics (TENX) - The Globe and Mail
Tenax Therapeutics CEO Christopher Giordano acquires $20,087 in shares By Investing.com - Investing.com South Africa
Tenax Therapeutics (TENX) CEO Christopher Giordano Buys 10,850 S - GuruFocus
Tenax Therapeutics CFO buys $10,981 in common stock - Investing.com
Tenax Therapeutics CFO buys $10,981 in common stock By Investing.com - Investing.com Canada
TENAX Therapeutics (NASDAQ: TENX) Reports Zero ING Groep N.V. and ING Capital Markets LLC Ownership on 37,423,917 Shares - Kalkine Media
ING Groep reports zero stake in Tenax Therapeutics (TENX) - Stock Titan
Tenax Therapeutics Stock Short Interest Rises to 35.39% - Quiver Quantitative
Wall Street Analysts Are Bullish on Top Healthcare Picks - The Globe and Mail
Cantor Fitzgerald reiterates Tenax Therapeutics stock rating at overweight By Investing.com - Investing.com South Africa
Cantor Fitzgerald reiterates Tenax Therapeutics stock rating at overweight - Investing.com
Tenax at Cantor conference: trial miss sharpens next-step strategy By Investing.com - Investing.com India
Tenax Therapeutics Updates Phase 3 LEVEL Trial Strategy - tipranks.com
Adar1 Capital Management, 10% owner, buys $1.6m in Tenax Therapeutics - Investing.com Australia
Adar1 Capital Management, 10% owner, buys $1.6m in Tenax Therapeutics By Investing.com - Investing.com South Africa
ADAR1 Capital Management, LLC Expands Tenax Therapeutics Inc (TE - GuruFocus
ADAR1 funds boost Tenax Therapeutics (TENX) stake in latest buy - Stock Titan
One manager just reported a 14% holding in Tenax Therapeutics (TENX) - Stock Titan
FMR LLC reports 514,925-share stake in Tenax (NASDAQ: TENX) - Stock Titan
TENX Form 4 FilingsTenax Therapeutics, Inc. SEC Form 4 - Stock Titan
TENX Jumps As Tenax Therapeutics Pivots Phase 3 Strategy - timothysykes.com
Tenax Therapeutics Stock Wobbles After Mixed Phase 3 Data - timothysykes.com
Tenax (TENX) Found a 26.3-Meter Benefit in a Prespecified Subgroup After LEVEL Missed Its Primary Endpoint. Is Another Phase 3 Trial Viable? - Yahoo Finance
Sphera Funds Management Boosts Tenax Therapeutics Stake in High-Risk Biotech Bet - GuruFocus
Investment funds tied to Tenax (TENX) 10% owner just bought more stock - Stock Titan
CCORF Maintains Tenax Therapeutics(TENX.US) With Buy Rating, Maintains Target Price $4 - Moomoo
Tenax Therapeutics to Participate in the 2026 Cantor Global Healthcare Conference - Stock Titan
TENX Downgraded by Guggenheim -- Rating Updated to Neutral - GuruFocus
Piper Sandler Maintains Tenax Therapeutics(TENX.US) With Buy Rating, Maintains Target Price $14 - Moomoo
Guggenheim Downgrades TENX to Neutral Amid Uncertain Clinical Ou - GuruFocus
Why is Tenax Therapeutics stock volatile today? By Investing.com - Investing.com Canada
Tenax Therapeutics (TENX) Phase 3 Data Spurs Focus on Subgroup B - GuruFocus
Tenax finds benefit in sicker patient subgroup after Phase 3 trial miss (TENX:NASDAQ) - Seeking Alpha
Tenax presents additional Phase 3 trial data for TNX-103 By Investing.com - Investing.com Nigeria
Tenax Therapeutics Announces Presentation of Phase 3 LEVEL Results in Late-Breaking Scientific Sessions at ESC Congress 2026 - Investing News Network
ING Groep reveals passive stake in Tenax Therapeutics (ING) - Stock Titan
New 5.3% backer emerges in Tenax Therapeutics (NASDAQ: TENX) - Stock Titan
Tenax Therapeutics Stock (TENX) Opinions on Recent Insider Purchases and Gains - quiverquant.com
Tenax rises on over $1.8M insider buying (TENX:NASDAQ) - Seeking Alpha
Tenax Therapeutics Inc Stock (TENX) Financials Data
Revenue
Net Income
Cash Flow
EPS
3.06%
2.55%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):